SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-22-000475
Filing Date
2022-04-22
Accepted
2022-04-22 16:33:59
Documents
1
Period of Report
2022-04-21

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 5288
  Complete submission text file 0000947871-22-000475.txt   7016
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Issuer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 36 ROBINSON ROAD, #13-01 CITY HOUSE SINGAPORE U0 068877
Business Address 36 ROBINSON ROAD, #13-01 CITY HOUSE SINGAPORE U0 068877 962 6 582 7999
BioLexis Pte Ltd. (Reporting) CIK: 0001716335 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37759 | Film No.: 22846034